We are live on ! Find out more
DSCI

Derma Sciences, Inc. Common Stock (DE)
DSCI

Delisted

DSCI was delisted on the 23rd of February, 2017.

66 hedge funds and large institutions have $180M invested in Derma Sciences, Inc. Common Stock (DE) in 2015 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

5% more funds holding

Funds holding: 6366 (+3)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

6% less capital invested

Capital invested by funds: $193M → $180M (-$12.3M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $232K

Holders
66
Holders Change
+3
Holders Change %
+4.76%
% of All Funds
1.76%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
4
Increased
27
Reduced
19
Closed
1
Calls
Puts
$232K
Net Calls
-$232K
Net Calls Change
+$302K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$29.3M -$675K -79,296 -2%
BC
2
Broadfin Capital
New York
$18M +$2.33M +273,600 +15%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$16.5M -$1.7K -200 -0%
CCM
4
Consonance Capital Management
New York
$13.8M
SM
5
Senvest Management
New York
$9.76M
Jennison Associates
6
Jennison Associates
New York
$9.63M +$2.23K +262 +0%
DM
7
Deerfield Management
New York
$8.39M +$2.3M +269,494 +37%
GPP
8
Great Point Partners
Connecticut
$8.28M -$1.77M -207,709 -18%
HM
9
HealthCor Management
New York
$7.57M -$225K -26,400 -3%
JGC
10
J. Goldman & Co
New York
$6.54M +$3.47M +407,649 +112%
BFA
11
BlackRock Fund Advisors
California
$5.25M +$14K +1,646 +0.3%
Vanguard Group
12
Vanguard Group
Pennsylvania
$4.94M +$335K +39,335 +7%
DCM
13
DAFNA Capital Management
California
$3.17M -$92.6K -10,876 -3%
PA
14
Perceptive Advisors
New York
$2.91M +$253K +29,701 +9%
RA
15
Royce & Associates
New York
$2.9M +$1.54M +180,500 +111%
O
16
OrbiMed
New York
$2.54M
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$2.33M +$345K +40,558 +17%
RAM
18
Roanoke Asset Management
New Jersey
$2.26M +$8.09K +950 +0.4%
Millennium Management
19
Millennium Management
New York
$2.24M +$1.86M +218,106 +471%
State Street
20
State Street
Massachusetts
$2.21M +$75.5K +8,860 +4%
GIM
21
Granahan Investment Management
Massachusetts
$2.1M -$696K -81,682 -25%
Northern Trust
22
Northern Trust
Illinois
$1.93M -$109K -12,855 -5%
BIT
23
BlackRock Institutional Trust
California
$1.91M -$3.53K -414 -0.2%
JP Morgan Chase
24
JP Morgan Chase
New York
$1.9M -$4.68M -549,641 -71%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.56M +$42K +4,934 +3%

DSCI Hedge Fund Activity: Q1 2015 in Review

66 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Derma Sciences, Inc. Common Stock (DE) (DSCI) for Q1 2015, worth a combined $180M — down 6.4% from $193M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new DSCI positions and 1 closed out — a net gain of 3 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was J. Goldman & Co, adding an estimated $3.47M. The largest seller was Teachers Advisors, cutting an estimated $29.8M.

  • 66 institutional investors held Derma Sciences, Inc. Common Stock (DE) (DSCI) as of Q1 2015, up from 63 in Q4 2014.
  • Funds reported $180M of Derma Sciences, Inc. Common Stock (DE) stock for Q1 2015, down 6.4% quarter-over-quarter.
  • 4 funds opened new Derma Sciences, Inc. Common Stock (DE) positions in Q1 2015 and 1 closed out, a net change of +3 holders.
  • The largest Derma Sciences, Inc. Common Stock (DE) buyer in Q1 2015 was J. Goldman & Co, an estimated $3.47M added.
  • The largest Derma Sciences, Inc. Common Stock (DE) seller in Q1 2015 was Teachers Advisors, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2015.